

Market Outlook

The Nifty 50 ended the week at 25,910, rebounding from the 25,500 level and recording a weekly gain of 1.64%. On the derivatives front, the 25,500 strike holds significant Put OI build-up, indicating a strong support zone where the index has also demonstrated resilience. On the upside, substantial Call OI accumulation at the 26,000 strike continues to exert selling pressure and acts as the immediate resistance level. From a technical perspective, the index remains in an ongoing consolidation phase on the daily chart. A decisive breakout on either side will be crucial for establishing the next directional move

Key Indices Update

INDEX	CLOSE	CHANGE (%)
NIFTY	25910.05	0.12
SENSEX	84562.78	0.10
BANKNIFTY	58517.55	0.23
INDIA VIX	11.93	-1.85

FII's STATISTICS


FII's F&O Data

Sector	Buy/Sell	Change in OI
Index Futures	-1873.27	4.51%
Index Options	10446.30	19.51%
Stock Futures	-316.19	-0.03%
Stock Options	-451.34	3.60%

FII's & DII's Cash Segment (Rs. In Crore)

Category	Amount	MTD	YTD
FII	-4968.22	-13653	-123873
DII	8461.47	41351	483801

FII's Activity in Index Future



Amt in Crores


NIFTY 50 HIGH DELIVERY STOCKS

SYMBOL	DELIVERABLE QTY	CHG IN DLY RATIO VS PREV DAY	% CHG IN TRD QTY OVER PREV DAY
ITC	56149205	28.3	867.48
ETERNAL	23318618	-0.5	-41.22
HDFCBANK	15669091	13.78	51.41
TMPV	14292112	5.91	65.85
BEL	7537808	0.8	61.91
SBIN	7101035	7.72	24.04
NTPC	6846707	10.26	26.03
ICICIBANK	6715125	-6.5	-47.01
POWERGRID	6063228	-8.31	-18.01
INFY	5702326	-19.5	-50.45


NIFTY

Nifty	25951.40
OI (In contracts)	272977
CHANGE IN OI (%)	5.10
PRICE CHANGE (%)	0.00
IMPLICATION	NEUTRAL

NIFTY (CLOSE VS OI)



NIFTY OPTION CHAIN




Long Buildup

Symbol	Price	Price %	OI	OI %
OIL	431.6	0.10	9116	11.80
BDL	1620.1	6.60	15459	7.40
INOXWIND	149.26	0.30	21523	7.30
MUTHOOTFIN	3739.7	10.10	12719	7.00
ANGELONE	2752.6	1.20	12545	6.80


BANKNIFTY

Banknifty	58644.40
OI (In contracts)	55059
CHANGE IN OI (%)	-0.50
PRICE CHANGE (%)	0.20
IMPLICATION	SHORT COVERING

BANKNIFTY (CLOSE VS OI)



BANKNIFTY OPTION CHAIN



Short Buildup

Symbol	Price	Price %	OI	OI %
TATATECH	681.4	-1.10	14127	8.70
EICHERMOT	6714.5	-1.80	19855	7.50
TMPV	392.85	-1.70	77905	6.50
SRF	2848.9	-2.10	19371	6.30
TATASTEEL	174.46	-1.40	48058	5.10

Top 10 High PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
PGEL	9387000	7696500	1.22
NATIONALUM	42393750	35006250	1.21
CANBK	127973250	106839000	1.2
MUTHOOTFIN	5265975	4522650	1.16
PETRONET	15154200	13248000	1.14
BPCL	19214775	17322725	1.11
ASIANPAINT	12035000	11084250	1.09
VOLTAS	5558625	5200125	1.07
AUROPARMA	4801500	4548500	1.06
POWERINDIA	304800	299350	1.02

Top 10 Low PCR Ratio Stocks

SCRIP	PUT	CALL	P/C RATIO
SHREECEM	57825	186475	0.31
GMRAIRPORT	45177075	142324875	0.32
NESTLEIND	1903500	5708000	0.33
ONGC	17455500	52965000	0.33
TATASTEEL	117782500	336281000	0.35
BLUESTARCO	986700	2732925	0.36
FORTIS	4108275	11456050	0.36
TVSMOTOR	2163175	5953850	0.36
APOLLOHOSP	934375	2515625	0.37
DELHIVERY	11155200	29877925	0.37

NIFTY 50 SUPPORT-RESISTANCE LEVELS

SYMBOL	R1	R2	PP	S1	S2
ADANIENT	2554	2589	2521	2486	2453
ADANIPTS	1529	1542	1515	1502	1488
APOLLOHOSP	7482	7527	7439	7394	7352
ASIANPAINT	2916	2933	2888	2871	2843
AXISBANK	1253	1262	1239	1229	1215
BAJAJ-AUTO	8868	8904	8824	8788	8744
BAJAJFINSV	2079	2090	2062	2051	2035
BAJFINANCE	1027	1033	1016	1010	999
BEL	431	434	425	422	417
BHARTIARTL	2115	2124	2102	2092	2079
CIPLA	1540	1546	1533	1527	1521
COALINDIA	393	399	388	383	378
DRREDDY	1253	1260	1243	1237	1227
EICHERMOT	6813	6912	6751	6652	6590
ETERNAL	308	312	301	297	290
GRASIM	2801	2816	2782	2766	2747
HCLTECH	1605	1615	1591	1581	1566
HDFCBANK	995	999	988	984	978
HDFCLIFE	781	788	777	770	765
HINDALCO	815	824	807	798	789
HINDUNILVR	2443	2455	2420	2407	2385
ICICIBANK	1385	1395	1377	1367	1358
INDIGO	5945	5970	5913	5888	5856
INFY	1523	1540	1508	1490	1475
ITC	411	413	407	405	401

SYMBOL	R1	R2	PP	S1	S2
JIOFIN	319	321	314	312	308
JSWSTEEL	1184	1200	1172	1157	1145
KOTAKBANK	2092	2100	2081	2073	2063
LT	4024	4040	3999	3983	3959
M&M	3728	3754	3696	3670	3637
MARUTI	15777	15855	15698	15620	15541
MAXHEALTH	1111	1119	1100	1093	1081
NESTLEIND	1281	1289	1273	1265	1256
NTPC	330	332	328	327	325
ONGC	250	253	248	246	244
POWERGRID	273	274	271	270	268
RELIANCE	1525	1530	1517	1512	1504
SBILIFE	2011	2018	1998	1990	1977
SBIN	974	980	965	959	950
SHRIRAMFIN	820	829	814	806	799
SUNPHARMA	1766	1774	1753	1746	1733
TATACONSUM	1168	1177	1156	1147	1134
TATASTEEL	177	180	175	172	170
TCS	3123	3137	3101	3087	3066
TECHM	1454	1467	1440	1427	1412
TITAN	3858	3882	3835	3811	3788
TMPV	399	406	394	388	383
TRENT	4425	4450	4383	4358	4316
ULTRACEMCO	11965	12040	11883	11808	11726
WIPRO	246	248	244	243	241

Research Team

Name	Email ID
<i>Ajit Mishra</i>	ajit.mishra@religare.com
<i>Abhijeet Banerjee</i>	abhijeet.banerjee@religare.com
<i>Gaurav Sharma</i>	gauravsharma2@religare.com
<i>Ashwani Harit</i>	ashwani.harit@religare.com
<i>Divya Parmar</i>	divya.parmar@religare.com
<i>Rajan Gupta</i>	rajan.gupta1@religare.com
<i>Vivek Chandra</i>	vivek.chandra@religare.com
<i>Himanshu Gupta</i>	himanshu.gupta1@religare.com
<i>Vishvajeet Singh</i>	vishvajeet.singh1@religare.com

Disclaimer

Before you use this research report, please ensure to go through the disclosure inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 and Research Disclaimer at the following link: <https://www.religareonline.com/disclaimer>

Specific analyst(s) specific disclosure(s) inter-alia as required under Securities and Exchange Board of India (Research Analysts) Regulations, 2014 is/are as under:

Statements on ownership and material conflicts of interest, compensation– Research Analyst (RA) [Please note that only in case of multiple RAs, if in the event answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) below, are given separately]:

S. No.	Statement	Answer	
		Yes	No
	I/we or any of my/our relative has any financial interest in the subject company? [If answer is yes, nature of Interest is given below this table]		No
	I/we or any of my/our relatives, have actual/beneficial ownership of one percent. or more securities of the subject company, at the end of the month immediately preceding the date of publication of the research report or date of the public appearance?		No
	I/we or any of my/our relative, has any other material conflict of interest at the time of publication of the research report or at the time of public appearance?		No
	I/we have received any compensation from the subject company in the past twelve months?		No
	I/we have managed or co-managed public offering of securities for the subject company in the past twelve months?		No
	I/we have received any compensation for brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation for products or services other than brokerage services from the subject company in the past twelve months?		No
	I/we have received any compensation or other benefits from the subject company or third party in connection with the research report?		No
	I/we have served as an officer, director or employee of the subject company?		No
	I/we have been engaged in market making activity for the subject company?		No

Nature of Interest if answer to F(a) above is Yes:

..... Name(s) with Signature(s) of RA(s).

[Please note that only in case of multiple RAs and if the answers differ inter-se between the RAs, then RA specific answer with respect to questions under F(a) to F(j) above, are given below]

SS. No.	Name(s) of RA.	Signatures of RA	Serial Question of question which the signing RA needs to make a separate declaration / answer	Yes	No

Copyright in this document vests exclusively with RBL. This information should not be reproduced or redistributed or passed on directly or indirectly in any form to any other person or published, copied, in whole or in part, for any purpose, without prior written permission from RBL. We do not guarantee the integrity of any emails or attached files and are not responsible for any changes made to them by any other person.

No representations are being made about the performance or activities unless accompanied by data regarding performance, disclosures of all the risk factors, etc. and disclaimer that "Such representations are not indicative of future results